ABL Bio Inc.
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
298380 | KO
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- South Korea
- Address:
- 서울 강남구 봉은사로 456 에이비엘바이오빌딩, 강남구
- Website:
- https://www.ablbio.com
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
ABL Bio Inc. is a clinical-stage biotechnology company that researches and develops novel antibody therapeutics, primarily focusing on bispecific antibodies. The company's core activities are concentrated in two main therapeutic areas: immuno-oncology and neurodegenerative diseases. For oncology, ABL Bio engineers bispecific antibodies and Antibody-Drug Conjugates (ADCs) designed to enhance anti-tumor immune responses and overcome resistance to existing treatments. In the neurodegenerative field, it utilizes a proprietary platform that enhances the penetration of the blood-brain barrier (BBB) to deliver therapeutics to the central nervous system for diseases like Parkinson's. A pioneer in its field in South Korea, ABL Bio was the first to advance a bispecific antibody platform into clinical trials in the country.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-09 00:00 |
Share Issue/Capital Change
주식매수선택권행사
|
Korean | 43.5 KB | ||
| 2025-09-09 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-09-09 00:00 |
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 24.2 KB | ||
| 2025-09-01 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과)
|
Korean | 16.4 KB | ||
| 2025-08-26 00:00 |
Share Issue/Capital Change
주식매수선택권부여에관한신고
|
Korean | 17.7 KB | ||
| 2025-08-12 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.4 MB | ||
| 2025-08-08 00:00 |
Legal Proceedings Report
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계…
|
Korean | 21.5 KB | ||
| 2025-07-23 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 7.0 KB | ||
| 2025-07-23 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-07-23 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-07-14 00:00 |
Share Issue/Capital Change
전환주식의전환청구권행사
|
Korean | 13.7 KB | ||
| 2025-07-09 00:00 |
Regulatory News Service
투자판단관련주요경영사항 (신규 항체-약물 결합체(ADC) 연구개발을 위한 기술도입 계약 해지)
|
Korean | 6.5 KB | ||
| 2025-07-04 00:00 |
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
|
Korean | 129.2 KB | ||
| 2025-06-11 00:00 |
Legal Proceedings Report
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계획 (…
|
Korean | 16.9 KB | ||
| 2025-06-04 00:00 |
Legal Proceedings Report
[기재정정]투자판단관련주요경영사항(임상시험계획승인신청등결정) (이중항체 면역항암제 ABL103의 제1b/2상 임상시험계…
|
Korean | 19.5 KB |
Automate Your Workflow. Get a real-time feed of all ABL Bio Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for ABL Bio Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
